The phase I/II clinical trial on 15 patients with moderate liver cirrhosis will be supervised by Professor Terui TERAI of Niigata University School of Medicine. For the treatment of liver cirrhosis, lysis of excessive extracellular matrix causing fibrosis, proliferation of hepatocytes, activation of hepatic progenitor cells, suppression of inflammatory response, etc. are effective, and such effects are thought to be demonstrated by humoral factors such as cytokines and growth factors produced by mesenchymal stem cells administered i.v. The ADR-1 mesenchymal stem cells derived from fat cells were expanded in Rohto’s proprietary automatic cell-culture system jointly developed with Kyoto’s Micronics Co.

Rohto Pharmaceutical news release, July 27, 2017